Evaluation of a monitored multiplate bioreactor for large-scale expansion of human periosteum derived stem cells for bone tissue engineering applications

Biochemical Engineering Journal

Volumn 108, Issue , 2016, Pages 58-68

  Lambrechts, T ^a   Papantoniou, I ^a,b   Viazzi, S ^a   Bovy, T ^c   Schrooten, J ^a   Luyten, F P ^a,b   Aerts, J M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^c ATMI Life Science   (Belgium)

Author keywords

Bioprocess monitoring; Bioreactors; In vivo bone formation; Scale up; Stem cell characterization; Tissue cell culture

Indexed keywords

BIOCONVERSION; BIOREACTORS; BONE; CELL CULTURE; CELLS; CYTOLOGY; MOLECULAR BIOLOGY; STEM CELLS; TISSUE; TISSUE CULTURE; TISSUE ENGINEERING;

BIOPROCESS MONITORING; BONE FORMATION; BONE TISSUE ENGINEERING; HOLOGRAPHIC IMAGING; MESENCHYMAL STEM CELL; METABOLITE CONCENTRATIONS; RECOVERY FRACTIONS; SCALE-UP;

CELL ENGINEERING;

DISSOLVED OXYGEN; GLUCOSE; LACTIC ACID; PLASTIC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOREACTOR; BIOREACTOR DESIGN; BONE TISSUE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; DOWNSTREAM PROCESSING; HOLOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LARGE SCALE PRODUCTION; MESENCHYMAL STEM CELL; MICROSCOPE; MOUSE; NONHUMAN; OSSIFICATION; PERIOSTEUM; PERIOSTEUM DERIVED STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROCESS MONITORING; QUALITY CONTROL; STEM CELL; STEM CELL CULTURE; STEM CELL EXPANSION; TISSUE ENGINEERING;

EID: 84959318767     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2015.07.015     Document Type: Article

References (49)

1. Heathman T.R., Nienow W., Mccall M.J., Coopman K., Kara B., Hewitt C.J. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen. Med. 2015, 10:49-64.
2. Dos Santos F., Campbell A., Fernandes-Platzgummer A., Andrade P.Z., Gimble J.M., Wen Y., et al. A xenogeneic-free bioreactor system for the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnol. Bioeng. 2014, 1-31. 10.1002/bit.25187.
3. Simaria A.S., Hassan S., Varadaraju H., Rowley J., Warren K., Vanek P., et al. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol. Bioeng. 2014, 111:69-83. 10.1002/bit.25008.
4. Bravery C.A., Carmen J., Fong T., Oprea W., Hoogendoorn K.H., Woda J., et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 2013, 15:9-19. 10.1016/j.jcyt.2012.10.008.
5. Sharma S., Raju R., Sui S., Hu W.-S. Stem cell culture engineering-process scale up and beyond. Biotechnol. J. 2011, 6:1317-1329. 10.1002/biot.201000435.
6. Placzek M.R., Chung I.-M., Macedo H.M., Ismail S., Mortera Blanco T., Lim M., et al. Stem cell bioprocessing: fundamentals and principles. J. R. Soc. Interface 2009, 6:209-232. 10.1098/rsif.2008.0442.
7. Rowley J., Abraham E., Campbell A., Brandwein H., Oh S. Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProcess Int. 2012, 10:16-22.
8. Want A.J., Nienow A.W., Hewitt C.J., Coopman K. Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask. Regen. Med. 2012, 7:71-84. 10.2217/rme.11.101.
9. Rodrigues C., Fernandes T., Diogo M., da Silva C., Cabral J. Stem cell cultivation in bioreactors. Biotechnol. Adv. 2011, 815-829.
10. Glassey J., Gernaey K.V., Clemens C., Schulz T.W., Oliveira R., Striedner G., et al. Process analytical technology (PAT) for biopharmaceuticals. Biotechnol. J. 2011, 6:369-377. 10.1002/biot.201000356.
11. Hanley P.J., Mei Z., Durett A.G., da Graca Cabreira-Harrison M., Klis M., Li W., et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the quantum cell expansion system. Cytotherapy 2014, 16:1449. 10.1016/j.jcyt.2014.01.417.
12. Jones M., Varella-Garcia M., Skokan M., Bryce S., Schowinsky J., Peters R., et al. Genetic stability of bone marrow-derived human mesenchymal stromal cells in the quantum system. Cytotherapy 2013, 15:1323-1339. 10.1016/j.jcyt.2013.05.024.
13. Sutlu T., Stellan B., Gilljam M., Quezada H.C., Nahi H., Gahrton G., et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010, 12:1044-1055. 10.3109/14653249.2010.504770.
14. De Bari C., Dell'Accio F., Luyten F.P. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum. 2001, 44:85-95. 10.1002/1529-0131(200101)44:185::AID-ANR123.0.CO;2-6.
15. Eyckmans J., Luyten F.P. Species specificity of ectopic bone formation using periosteum-derived mesenchymal progenitor cells. Tissue Eng. 2006, 12:2203-2213.
16. Roberts S.J., van Gastel N., Carmeliet G., Luyten F.P. Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath. Bone 2014, 70:10-18. 10.1016/j.bone.2014.08.007.
17. King J.A., Miller W.M. Bioreactor development for stem cell expansion and controlled differentiation. Curr. Opin. Chem. Biol. 2008, 11:394-398.
18. Thomas R.J., Hourd P.C., Williams D.J. Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. J. Biotechnol. 2008, 136:148-155. 10.1016/j.jbiotec.2008.06.009.
19. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317. 10.1080/14653240600855905.
20. Bianco P., Cao X., Frenette P.S., Mao J.J., Robey P.G., Simmons P.J., et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med. 2014, 19:35-42. 10.1038/nm.3028.
21. Eyckmans J., Roberts S.J., Schrooten J., Luyten F.P. A clinically relevant model of osteoinduction: a process requiring calcium phosphate and BMP/Wnt signalling. J. Cell. Mol. Med. 2010, 14:1845-1856. 10.1111/j.1582-4934.2009.00807.x.
22. De Bari C., Dell'Accio F., Vanlauwe J., Eyckmans J., Khan I.M., Archer C.W., et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum. 2006, 54:1209-1221. 10.1002/art.21753.
23. Castillo J., Egloff M., Collignon F., Goffinet J., Drugmand J. Transfer of hepatic progenitor stem cell culture process from multiple tray stacks to the xpansion multiplate bioreactor. Cytotherapy 2013, 15:S20. 10.1016/j.jcyt.2013.01.074.
24. Egloff M., Castillo J. Scaling up stem cells. BioProcess Int. 2012, 10:62-64. 10.1089/gen.33.2.17.
25. Sonnaert M., Papantoniou I., Luyten F.P., Schrooten J. Quantitative validation of the Presto Blue™ metabolic assay for on-line monitoring of cell proliferation in a 3D perfusion bioreactor system. Tissue Eng. Part C 2014, (ahead of print). http://www.ncbi.nlm.nih.gov/pubmed/25336207.
26. Jin H., Bae Y., Kim M., Kwon S.-J., Jeon H., Choi S., et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int. J. Mol. Sci. 2013, 14:17986-18001. 10.3390/ijms140917986.
27. Baksh D., Yao R., Tuan R.S. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007, 25:1384-1392. 10.1634/stemcells.2006-0709.
28. van Harmelen V., Röhrig K., Hauner H. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. Metabolism 2004, 53:632-637. 10.1016/j.metabol.2003.11.012.
29. Sonnaert M., Papantoniou I., Bloemen V., Kerckhofs G., Luyten F.P., Schrooten J. Human periosteal-derived cell expansion in a perfusion bioreactor system: proliferation, differentiation and extracellular matrix formation. J. Tissue Eng. Regen. Med. 2014, 1:1-12. 10.1002/term.1951.
30. Papantoniou I., Chai Y., Luyten F.P., Schrooten J. Process quality engineering for bioreactor-driven manufacturing of tissue-engineered constructs for bone regeneration. Tissue Eng. Part C 2013, 19:1-14.
31. Pattappa G., Heywood H.K., de Bruijn J.D., Lee D.A. The metabolism of human mesenchymal stem cells during proliferation and differentiation. J. Cell. Physiol. 2011, 226:2562-2570. 10.1002/jcp.22605.
32. Kasper C., van Griensven M., Pörtner R. Bioreactor Systems for Tissue Engineering II: Strategies for the Expansion and Directed Differentiation of Stem Cells 2010, vol. 2. Springer Science & Business Media.
33. Lambrechts T., Papantoniou I., Sonnaert M., Schrooten J., Aerts J.-M. Model-based cell number quantification using online single-oxygen sensor data for tissue engineering perfusion bioreactors. Biotechnol. Bioeng. 2014, 111:1982-1992. 10.1002/bit.25274.
34. Schop D., Janssen F.W., Van Rijn L.D.S., Fernandes H., et al. Growth, metabolism, and growth inhibitors of mesenchymal stem cells. Tissue Eng. Part A 2009, 15:1877-1886.
35. Higuera G., Schop D., Janssen F., van Dijkhuizen-Radersma R., van Boxtel T., van Blitterswijk C.A. Quantifying in vitro growth and metabolism kinetics of human mesenchymal stem cells using a mathematical model. Tissue Eng. Part A 2009, 15:2653-2663. 10.1089/ten.TEA.2008.0328.
36. Sart S., Agathos S.N., Li Y. Process engineering of stem cell metabolism for large scale expansion and differentiation in bioreactors. Biochem. Eng. J. 2014, 84:74-82. 10.1016/j.bej.2014.01.005.
37. Cunha B., Aguiar T., Silva M.M., Silva R., Sousa M.F.Q., Pineda E., et al. Exploring continuous and integrated strategies for the up- and downstream processing of human mesenchymal stem cells. J. Biotechnol. 2015, 1-12. 10.1016/j.jbiotec.2015.02.023.
38. Delahaye M., Lawrence K., Ward S., Hoare M. An ultra scale-down analysis of the recovery by dead-end centrifugation of human cells for therapy. Biotechnol. Bioeng. 2014, 10.1002/bit.25519.
39. Cunha B., Peixoto C., Silva M.M., Carrondo M.J.T., Serra M., Alves P.M. Filtration methodologies for the clarification and concentration of human mesenchymal stem cells. J. Membr. Sci. 2015, 478:117-129. 10.1016/j.memsci.2014.12.041.
40. Roberts S.J., Geris L., Kerckhofs G., Desmet E., Schrooten J., Luyten F.P. The combined bone forming capacity of human periosteal derived cells and calcium phosphates. Biomaterials 2011, 32:4393-4405.
41. Chai Y.C., Kerckhofs G., Roberts S.J., Van Bael S., Schepers E., Vleugels J., et al. Ectopic bone formation by 3D porous calcium phosphate-Ti6Al4V hybrids produced by perfusion electrodeposition. Biomaterials 2012, 33:4044-4058. 10.1016/j.biomaterials.2012.02.026.
42. Bravery C.A., Carmen J., Fong T., Oprea W., Hoogendoorn K.H., Woda J., et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 2013, 15:9-19. 10.1016/j.jcyt.2012.10.008.
43. Mastri M., Shah Z., McLaughlin T., Greene C.J., Baum L., Suzuki G., et al. Activation of Toll-like receptor 3 (TLR3) amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. AJP Cell Physiol. 2012, 303:1-21. 10.1152/ajpcell.00191.2012.
44. Jenkins M.J., Farid S.S. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. Biotechnol. J. 2015, 10:83-95. 10.1002/biot.201400348.
45. Bara J.J., Richards R.G., Alini M., Stoddart M.J. Concise review: bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells 2014, 32:1713-1723. 10.1002/stem.1649.
46. Whitfield M.J., Lee W.C.J., Van Vliet K.J. Onset of heterogeneity in culture-expanded bone marrow stromal cells. Stem Cell Res. 2013, 11:1365-1377. 10.1016/j.scr.2013.09.004.
47. Sepúlveda J., Tomé M. Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model. Stem Cells 2014, 1865-1877.
48. Sart S., Agathos S.N., Li Y. Engineering stem cell fate with biochemical and biomechanical properties of microcarriers. Biotechnol. Prog. 2013, 29:1354-1366. 10.1002/btpr.1825.
49. Chen A.K.-L., Chen X., Choo A.B.H., Reuveny S., Oh S.K.W. Critical microcarrier properties affecting the expansion of undifferentiated human embryonic stem cells. Stem Cell Res. 2011, 7:97-111. 10.1016/j.scr.2011.04.007.